Product Information

KEVZARA 200 MG/1.14 ML SYRINGE is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $2081.3553 per ML under NDC 00024591001. Its NADAC has been published 49 times since Dec 17, 2025.

KEVZARA 200 MG/1.14 ML SYRINGE

sarilumab
$2081.3553per ML

Strength

200 mg/1.14mL

NDC

00024591001

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

11/18/2026

Active Ingredients

SARILUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA761037

On Market Since

5/22/2017

Pharmacological Classes

Interleukin 6 Receptor Antagonists
Interleukin-6 Receptor Antagonist

Price Statistics

The NADAC for KEVZARA 200 MG/1.14 ML SYRINGE has been published 49 times since Dec 17, 2025, and over the history we have for it it has risen 6.8%. The table below summarizes its recorded NADAC range and movement.

Current price$2081.3553 per ML
All-time high$2081.3553 (Nov 18, 2026)
All-time low$1949.5114 (Dec 17, 2025)
52-week high$2081.3553
52-week low$1949.5114
Median price$2066.4821
Average price$2060.0793
Largest weekly change+6.0% (Jan 7, 2026)
Weeks tracked49
Tracking sinceDec 17, 2025

Price History

1W

+0.5%

1M

+0.5%

3M

+0.7%

6M

+0.7%

1Y

N/A

3Y

N/A

5Y

N/A

All

+6.8%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 0%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of KEVZARA 200 MG/1.14 ML SYRINGE?

The current National Average Drug Acquisition Cost (NADAC) for KEVZARA 200 MG/1.14 ML SYRINGE, manufactured by Sanofi-Aventis U.S. LLC, is $2081.3553 per ML (NDC 00024591001), effective Nov 18, 2026.

How has the price of KEVZARA 200 MG/1.14 ML SYRINGE changed over time?

Over the history we have for it, the NADAC for KEVZARA 200 MG/1.14 ML SYRINGE has risen 6.8%. It has been tracked across 49 weekly CMS publications since Dec 17, 2025.

What are the highest and lowest recorded NADAC prices for KEVZARA 200 MG/1.14 ML SYRINGE?

Since Dec 17, 2025, the NADAC for KEVZARA 200 MG/1.14 ML SYRINGE has ranged from a low of $1949.5114 (Dec 17, 2025) to a high of $2081.3553 (Nov 18, 2026), with a median of $2066.4821 per ML.

Are there cheaper alternatives to KEVZARA 200 MG/1.14 ML SYRINGE?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, KEVZARA 200 MG/1.14 ML PEN INJ, is $2072.9399 per ML — about 0% below KEVZARA 200 MG/1.14 ML SYRINGE.

Who manufactures KEVZARA 200 MG/1.14 ML SYRINGE?

KEVZARA 200 MG/1.14 ML SYRINGE (NDC 00024591001) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.